Analyst Upgrades

• Cree (CREE) and Rubicon Technology (RBCN) to buy from neutral at Merriman.
• Children's Place (PLCE) to outperform from market perform at BMO Capital.
• Lockheed Martin (LMT) to neutral from underperform at BofA/Merrill.
• Copano Energy (CPNO) to outperform from market perform at Morgan Keegan.
• Motorola Mobility (MMI) to neutral from reduce at Nomura.
• Parker-Hannifin (PH) to buy from hold at KeyBanc.
• Akamai (AKAM), ShoreTel (SHOR), AMB Property (AMB) and ProLogis (PLD) to buy from hold at Stifel Nicolaus.

Analyst Upgrades

• Applied Materials (AMAT) to overweight from neutral at Piper Jaffray.
• Air Products (APD) to buy from hold at Citigroup.
• Youku.com (YOKU) and Pinnacle West (PNW) to buy from neutral at Goldman.
• Stryker (SYK) and Zimmer (ZMH) to buy from neutral at UBS.
• Zions Bancorp (ZION) to outperform from neutral at Macquarie.
• Alnylam (ALNY) to buy from hold at Needham.
• AK Steel (AKS) to buy from hold at KeyBanc.

Analyst Upgrades

• FBR Capital upgraded Microsoft (MSFT) to outperform from market perform, citing valuation and the ongoing corporate PC cycle refresh. The firm upped its target for shares to $32 from $31.
• Oppenheimer upgraded BP (BP) to outperform from perform with a $55 price target as it sees greater upside potential than downside risk from the oil spill.
• Wunderlich upgraded Stericycle (SRCL) to hold from sell and raised its target for shares to $50 from $42, citing the company's alliance with Republic Services (RSG).
• Illinois Tool Works (ITW) was upgraded to overweight from equal weight at Barclays.
• GameStop (GME) was upgraded to buy from neutral at Janney Montgomery.
• Fluor (FLR) was upgraded to buy from neutral at Goldman.

Analyst Upgrades

• Piper Jaffray upgraded UPS (UPS) to overweight from neutral with a $79 price target following the company's better-than-expected Q1 results.
• SunTrust believs Zions Bancorp's (ZION) tangible book value is around $20/share, making any future capital raise not as dilutive as the firm previously expected. The firm upgraded shares to buy from neutral and has a $26 target on the stock.
• FBR Capital upgraded J.B. Hunt (JBHT) to outperform from market perform following the company's better-than-expected Q1 results. The firm raised its target price for shares to $43 from $40.
• American Superconductor (AMSC) was upgraded to buy from hold at Deutsche Bank.
• BP (BP) was upgraded to outperform from neutral at Credit Suisse.
• Global Payments (GPN) was upgraded to outperform from market perform at Wells Fargo.

Analyst upgrades:

• FBR Capital upgraded McAfee (NYSE: MFE) to Outperform from Market Perform after channel checks indicated the company's September quarter deal flow has been stronger than expected. FBR raised its target on shares to $50 from $41.
• Thomas Weisel upgraded Adtran (NASDAQ: ADTN) to Overweight from Market Weight, citing increased wireless backhaul capex spending by Tier-1 carriers. The firm raised its target to $32 from $21.
• RBC Capital upgraded Brunswick (NYSE: BC) to Outperform from Sector Perform as the firm thinks the company no longer has liquidity risk and can generate significant profits by 2012. The firm set a $17 target on the stock.
• Bronco Drilling (NASDAQ: BRNC) was upgraded to Hold from Underperform at Jefferies.
• LSI Corp. (NYSE: LSI) was upgraded to Buy from Hold at Deutsche Bank.
• UBS upgraded U.S. Airways (NYSE: LCC) and UAL Corp. (NASDAQ: UAUA) to Buy from Neutral.

When my son had a huge boil under his arm, it turned out that it was filled with the killer staph, MRSA. It also turns out that my (otherwise) great doctor used a traditional lab to process the test, which took a week to determine it was MRSA.

Cepheid (NASDAQ: CPHD) manufactures the equipment and test that takes just two hours to do the same thing -- and is better and cheaper than traditional tests. CPHD wins 90%-plus of all competitive bids and its test could be available in low-tech facilities, such as doctor's offices or nursing homes, next year.

The big catalyst for this stock, however, is that Medicare will stop paying for all hospital-acquired infections except MRSA in October. So institutions need a quick test if they are going to be reimbursed for treatment.

The stock has fallen from $30 to under $9. It's worth $20 - $22 to an acquirer.

Your best strategy for life-changing profits?

Buy the call options.

Next: Biotech Stock #4

Analyst upgrades:

• Societe General upgraded BASF AG (OTC: BASFY) to Buy from Hold. The firm believes the bad news is out and that BASF has a strong market position.
  
• Pali Capital upgraded Hot Topic (NASDAQ: HOTT) to Buy from Neutral based on the ongoing merchandise catalyst, the opportunity to reclaim the mainstream kid and closing underperforming stores, which create the most favorable conditions in the last 5+ years.
  
• Stanford upgraded L-1 Identity (NYSE: ID) to Buy from Hold on valuation, and the firm sees little risk to the company from the Obama Administration.
• Gymboree (NASDAQ: GYMB) and Windstream (WIN) were raised to Overweight from Neutral at JP Morgan.
  
• Doral Financial (NYSE: DRL) was upgraded at B. Riley to Buy from Neutral.
  
• Alumina (NYSE: AWC) was upgraded to Buy from Neutral at UBS.

Analyst downgrades:

• Credit Suisse downgraded Targanta (NASDAQ: TARG) to Underperform from Outperform following the FDA Panel's rejection of Oritavancin.
  
• Citigroup downgraded BASF AG (OTC: BASFY) to Sell from Hold and sees no reason to own the stock following the company's profit warning. Shares were also downgraded at WestLB to Hold from Add.
  
• Deutsche Bank downgraded shares of Amedisys (NASDAQ: AMED) to Hold from Buy and lowered its target to $53 from $75 on concerns over the company's deteriorating A/R aging trends.
• VeriFone Holdings (NYSE: PAY) and Navios Maritime (NYSE: NMM) were lowered to Neutral from Overweight at JP Morgan.
  
• NTT DoCoMo (NYSE: DCM) was downgraded at Citigroup to Hold from Buy.

Analyst initiations:

• Needham expects shares of Cepheid (NASDAQ: CPHD) to be driven by continued market penetration in the hospital acquired infection market, new test introductions, GeneXpert Infinity sales, and molecular diagnostics growth from sales outside of traditional molecular testing areas. Shares were initiated with a Buy rating and $21 target.
  
• Needham also initiated Gen-Probe (NASDAQ: GPRO) with a Hold rating and expects market share gains for the company when PANTHER is approved in 2010/2011.
  
• William Blair believes Harbin Electric (NASDAQ: HRBN) is an "interesting" opportunity for exposure to rapid growth in infrastructure within the People's Republic of China. The firm started shares with a Market Perform rating.
• Boston Scientific (NYSE: BSX) was initiated with a Buy rating and $11 target at UBS.
  
• NutriSystem (NASDAQ: NTRI) was initiated with a Neutral rating at Janney Montgomery.
  
• Ener1 (NYSE: HEV) was assumed at JMP Securities with an Outperform rating and $9 target.
  

Analyst upgrades:

• Goldman upgraded Bed Bath & Beyond (NASDAQ: BBBY) to Buy from Neutral based on valuation and a potential margin rebound at Linens N' Things.
  
• Citigroup upgraded Rockwell Automation Inc. (NYSE: ROK) to Hold from Sell on valuation and believes expectations have been reset to a reasonable level. The company's target was lowered to $27 from $33.
  
• Friedman Billings upgraded shares of Ceradyne (NASDAQ: CRDN) to Outperform from Market Perform on valuation following the recent weakness and thinks the Army will move forward with a larger XSAPI procurement in FY09. The firm raised their target to $30 from $26.
• Goldman added Wyeth (NYSE: WYE) to the Conviction Buy List.
  
• Equity Residential (NYSE: EQR) was upgraded to Buy from Neutral at UBS.
  
• Analog Devices (NYSE: ADI) was raised to Overweight from Equal Weight at Morgan Stanley.

Analyst downgrades:

"I still love Cepheid (NASDAQ: CPHD)," says biotechnology sector expert Michael Shulman in his ChangeWave Biotech Investor.

The advisor explains, "Cepheid does genetic testing of the things that can make us sick or kill us. The company is at the forefront of the next generation of diagnostics testing, and has real products already on the market." Here is his review.

"Cepheid has had outrageous sales success in the past few quarters and, therefore, has excellent profits looming. However, the true value for the company is its long-term potential.

"CPHD broke out about a year ago with a new test for the killer staph infection, MRSA, and the test is an order-of-magnitude better than any the competition has.

"A combination of tremendous public pressure and a CDC report that said MRSA kills at least 17,000 people per annum (and consumes billions of dollars, already), have hospitals everywhere putting in MRSA screening and prevention programs. And nine out of 10 of those hospitals are buying CPHD's equipment and tests.

MOST NOTEWORTHY: Learning Tree, Shengdatech and Cepheid were today's noteworthy initiations:

• B. Riley initiated Learning Tree (NASDAQ:LTRE) with a Buy rating and $24 target. The firm believes investors have an opportunity to invest in a compelling revenue growth/margin expansion story at reasonable multiples with the stock off recent highs.
  
• Merriman started Shengda Tech (NASDAQ:SDTH) with a Buy rating and points to the company's growing nano-particle business and the vast market expansion opportunities associated with this business.
  
• Stephens believes Cepheid (NASDAQ:CPHD) possesses a best-in-class platform for molecular diagnostic testing with a virtual monopoly in the molecular point of care market; shares were assumed with an Overweight rating and $32 target.

OTHER INITIATIONS:

• Visa (NYSE:V) was started at Morgan Keegan with a Market Perform rating.
  
• Morgan Stanley initiated Dr. Pepper Snapple (N YSE:DPS) with an Equal Weight rating and $30 target.
  
• Goldman initiated Kraft Foods (NYSE:KFT) with a Neutral rating.

In referring to his recommended position in Cepheid (NASDAQ: CPHD), industry-leading biotech expert Michael Shulman jests, "To use a highly technical financial term: WooHoo! What a great quarter capped by a justifiably upbeat conference call."

Here, the editor of The ChangeWave Biotech Investor takes a look at the company, noting "I've been pounding the table for CPHD -- and this great quarter justifies my optimism."

"Cepheid develops and markets a diagnostic testing system called the GeneXpert that's a hardware platform for genetic tests of diseases that can be identified by their genetic code.

""There are several specific tests for this platform including MRSA, the killer staph infection that is typically found in hospitals, but is also spreading to other venues.

"In its latest quarrter, the company reported that revenues were $36.3 million, up 53% from Q3 2006. Total product sales were $34 million, up 50% and clinical product sales were $20.7 million, up 258%.

In its latest quarrter, the company reported that revenues were $36.3 million, up 53% from Q3 2006. Total product sales were $34 million, up 50% and clinical product sales were $20.7 million, up 258%.

"The GeneXpert system sales exploded! By the end of the quarter 1,376 GeneXpert System modules were installed in hospitals in the United States -- including 77 in VA hospitals, up by 51 modules in Q3 and representing a 79% share of the VA market.

MOST NOTEWORTHY: UBS AG, Cepheid and ICT Group were today's noteworthy upgrades:

• Credit Suisse upgraded shares of UBS AG (NYSE: UBS) to Outperform from Neutral on valuation, as they believe the current share price implies a negative valuation of the company's securities unit.
• Piper upgraded shares of Cepheid (NASDAQ: CPHD) to Buy from Neutral to reflect the better-than-expected quarter to date GeneXpert placements and management's bullish outlook during their Annual Health Care Conference.
• ICT Group (NASDAQ: ICTG) was upgraded to Market Perform from Underperform at Friedman Billings following the company's reiteration of guidance last night. The firm believes shares are near a floor and that the company could be an attractive takeout candidate once business stabilizes.

OTHER UPGRADES:

• Deutsche Bank upgraded British Airways (OTC: BAIRY) to Buy from Hold.
• Lehman upgraded the packaging sector to Positive from Neutral and upgraded AptarGroup (NYSE: ATR) to Equal Weight from Underweight.
• JP Morgan upgraded Potash Corp. (NYSE: POT) to Overweight from Neutral.

MOST NOTEWORTHY: Credit Suisse, Deutsche Bank, ConocoPhillips, Finisar and Cepheid were today's noteworthy downgrades:

• Lehman Brothers downgraded shares of Credit Suisse Group (NYSE: CS) to Equal Weight from Overweight and shares of Deutsche Bank AG (NYSE: DB) to Underweight from Overweight to reflect potential write downs from their U.S. subprime mortgage exposure.
• ConocoPhillips (NYSE: COP) was downgraded to Market Perform from Outperform at Bernstein on valuation.
• Needham lowered shares of Finisar Corporation (NASDAQ: FNSR) to Buy from Strong Buy, as they expect pressure in FY08 as margins recover and opex remains elevated due to patent litigation.
• Cepheid Inc (NASDAQ: CPHD) was downgraded at UBS to Neutral from Buy on valuation.

OTHER DOWNGRADES:

• Calyon downgraded shares of Gol Linhas Aereas (NYSE: GOL) and TAM SA (NYSE: TAM) to Add from Buy.
• Goldman Sachs downgraded Altria Group Inc (NYSE: MO) to Neutral from Buy.
• Morgan Stanley downgraded NeurogesX (NASDAQ: NGSX) to Equal Weight from Overweight.
• Friedman Billings downgraded shares of Brookline Bancorp (NASDAQ: BRKL) to Market Perform from Outperform.

In a move that could complement its other recent acquisitions, Roche Holding Ltd (OTC: RHHBY) yesterday made a $75-a-share hostile bid for Ventana Medical Systems, Inc (NASDAQ: VMSI). The $3 billion cash offer would allow Roche to gain a test Ventana developed to screen patients who could respond to the Swiss pharmaceutical giant's breast cancer medicine, Herceptin. The main goal of acquiring Ventana would be to "move closer toward delivering tools to select the right drugs for the right patients, rather than saving costs," Roche CEO Franz Humer told the Wall Street Journal.

Roche has already agreed to three other diagnostic acquisitions this year: The company agreed to buy CuraGen Corporation's (NASDAQ: CRGN) 454 Life Sciences in March for $140 million, allowing it to gain the company's DNA-mapping technology, and later agreed to acquire BioVeris Corporation (NASDAQ: BIOV) for $600 million and NimbleGen Systems for $272.5 million. The acquisition of BioVeris will add a screening technology that stimulates cells to emit light, while the NimbleGen acquisition would add more genetic tools for drug research.

Should an acquisition be seen as a sure thing? No, executives at Ventana said. Although Roche has made several friendly efforts to engage in "meaningful discussions" with Ventana's chairman and board concerning a transaction, Ventana has so far rebuffed Roche. The company advised shareholders in taking any action in response to the offer, but said the Board would review Roche's offer and make a recommendation within 10 days. What may make this particular offer different is that the $75-per-share offer was nearly 45% higher than Ventana's closing price of $51.74 yesterday.

In the event of an acquisition, Roche said it would operate Ventana as a separate unit within its diagnostics division, allowing it to retain its management team and employees as well as its headquarters in Arizona. This would be a similar agreement to the one Roche maintains with U.S. biotech company Genentech Inc (NYSE: DNA), which is majority-owned by Roche but is managed as an independent company.

Based on a potential acquisition, analysts believe that biotechnology companies Gen-Probe Incorporated (NASDAQ: GPRO), Luminex Corporation (NASDAQ: LMNX) and Cepheid Inc (NASDAQ: CPHD) could be potential acquisition targets based on their technology platforms and product offerings.

MOST NOTEWORTHY: Marriott International (MAR), VeriFone Holdings, Inc (PAY), Generex Biotechnology Corp (GNBT), Quality Systems, Inc (QSII) and Owens Corning (OC) were today's noteworthy initiations:

• Friedman Billings views Marriott International's (NYSE: MAR) relatively low-risk, capital efficient fee income model as an attractive investment opportunity and started shares with an Outperform rating.

• Wedbush believes VeriFone Holdings (NYSE: PAY) is on the highest quality names in the space given the company's superior growth, high margins and consistent execution and started shares with a Strong Buy rating.

• Rodman believes Generex Biotech's (NASDAQ: GNBT) oral insulin, Oral-lyn could be a significant player in the non-injectable insulin market and initiated shares with an Outperform rating.

• Quality Systems (NASDAQ: QSII) was initiated with a Market Weight rating at Thomas Weisel.

• Morgan Keegan started Owens Corning (NYSE: OC) with a Market Perform rating citing the slowdown in the North American housing market.

OTHER INITIATIONS:

• William Blair started Cepheid (NASDAQ: CPHD) with an Outperform rating.

• Kaufman started Glu Mobile Inc (NASDAQ: GLUU) with a Buy rating.

• Fuel Tech Inc (NASDAQ: FTEK) was started with a Buy rating.

• Wedbush initiated shares of Hypercom Corp (NYSE: HYC) with a Hold rating.

• Archer Daniels Midland Co (NYSE: ADM) was initiated with an Accumulate rating at Buckingham.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).